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Abstract
Background: Headache is disabling and prevalent in idiopathic intracranial hypertension. Therapeutic lumbar punctures
may be considered to manage headache. This study evaluated the acute effect of lumbar punctures on headache severity.
Additionally, the effect of lumbar puncture pressure on post-lumbar puncture headache was evaluated.
Methods: Active idiopathic intracranial hypertension patients were prospectively recruited to a cohort study, lumbar
puncture pressure and papilloedema grade were noted. Headache severity was recorded using a numeric rating scale
(NRS) 0–10, pre-lumbar puncture and following lumbar puncture at 1, 4 and 6 hours and daily for 7 days.
Results: Fifty two patients were recruited (mean lumbar puncture opening pressure 32 (28–37 cmCSF). At any point in
the week post-lumbar puncture, headache severity improved in 71% (but a small reduction of 1.1 2.6 numeric rating
scale) and exacerbated in 64%, with 30% experiencing a severe exacerbation 4 numeric rating scale. Therapeutic
lumbar punctures are typically considered in idiopathic intracranial hypertension patients with severe headaches
(numeric rating scale 7). In this cohort, the likelihood of improvement was 92% (a modest reduction of headache
pain by 3.0 2.8 numeric rating scale, p¼ 0.012, day 7), while 33% deteriorated. Idiopathic intracranial hypertension
patients with mild (numeric rating scale 1–3) or no headache (on the day of lumbar puncture, prior to lumbar puncture)
had a high risk of post- lumbar puncture headache exacerbation (81% and 67% respectively). Importantly, there was no
relationship between lumbar puncture opening pressure and headache response after lumbar puncture.
Conclusion: Following lumbar puncture, the majority of idiopathic intracranial hypertension patients experience some
improvement, but the benefit is small and post-lumbar puncture headache exacerbation is common, and in some
prolonged and severe. Lumbar puncture pressure does not influence the post-lumbar puncture headache.
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Background
Idiopathic intracranial hypertension (IIH) is a disease
of unknown aetiology typically manifesting in obese
females aged 20 to 40 (1,2). There is a risk of severe
visual loss occurring (in up to one quarter of patients
(3)) but for the majority of patients the day-to-day real-
ity is one of a chronic disease, dominated by disabling
headaches which significantly reduce quality of life
(4–6). The incidence of IIH appears to be rising with
global obesity rates and many patients will have
repeated hospital admissions for assessment and treat-
ment (7–10).
Lumbar punctures (LPs) occur at diagnosis and are
sometimes repeated during the course of the illness to
evaluate disease status. Some centres also perform
therapeutic LPs to manage headache pain (11).
Complications of LPs are well documented and include
local discomfort, post-dural puncture headache, severe
anxiety and discomfort, and more rarely cerebrospinal
fluid (CSF) infection, localised haematoma and para-
paresis (12,13). There is also increasing awareness of
the emotional costs and procedure-induced anxiety
noted by IIH patients. We have also observed post-
LP headache exacerbation in IIH patients, which can
precipitate a further medical consultation, attendance
at the hospital emergency department, and even hos-
pital admission. The risk of headache exacerbation
post-LP has not been previously characterised in IIH.
There is a lack of prospective data describing the
improvement and exacerbations in IIH headaches in
the week post-LP. This study aimed to evaluate the
temporal change in headache severity in the week fol-
lowing a standardised LP, in patients with active IIH.
Furthermore, we aimed to stratify the response to LP
by baseline headache severity and evaluate the extent of
improvement and the likelihood of an exacerbation.
Importantly, we also sought to define the influence of
LP opening pressure on post-LP headache.
Methods
Participants
Patients with IIH were prospectively recruited from the
out-patients department at University Hospitals
Birmingham NHS Foundation Trust, a United
Kingdom tertiary referral hospital. Patients were
asked to consent to LP for research purposes.
Eligibility criteria included fulfilment of the updated
modified Dandy criteria (no evidence of intracranial
pathology or venous sinus thrombosis (magnetic reson-
ance or computerised tomography imaging and venog-
raphy at diagnosis) and LP opening pressure 25
cmCSF) (14). Consequently, all patients had undergone
a previous diagnostic LP. Only those with active IIH
(papilloedema with a Frise´n grade 1 and LP opening
pressure 25 cmCSF) at the time of the study recruit-
ment were included (14,15). To avoid recruitment bias,
all those prospectively screened that met the eligibility
criteria were informed of the study and offered
recruitment.
Patient consents
Patients gave written informed consent to participate in
the study. The study was conducted according to the
Declaration of Helsinki and approval was obtained
through Research Ethics Committees (13/YH/0366
and 14/WM/0011).
Patient assessment
Eligibility was confirmed following assessment by a
neuro-ophthalmological examination, which included
fundus photography with subsequent grading of the
papilloedema (Frise´n grade 0–5, most severe) per-
formed by three masked reviewers. Patient demograph-
ics were recorded.
A standardised LP was performed: A Quincke type
point, 20GA 3.50 IN, 0.9mm 90mm (Becton
DickinsonTM, Spain) spinal needle was used. An ultra-
sound scan was used to mark the LP position with
measurement of the CSF depth from the skin recorded.
LPs were performed in the left lateral decubitus pos-
ition and, following dural puncture, legs were repos-
itioned to mitigate against compressing the abdomen.
A stabilised reading was recorded once any fluctuations
in the manometer settled. After measurement of the
opening pressure, a standardised volume of CSF was
drained (estimated at 10ml) and finally a closing pres-
sure was recorded. CSF red cell count was evaluated in
the University Hospital Birmingham NHS Foundation
Trust laboratory.
Headache evaluation
Headache phenotype was characterised according to
the International Headache Society ICHD-3 beta clas-
sification at baseline by a headache specialist (16).
Headache preventative medications, acetazolamide
use and acute analgesic use on the day of LP were rec-
orded. Headache severity was evaluated using a
Numeric Rating Scale (NRS, 0 (no pain) to 10 (most
severe pain)). Headache severity NRS was prospect-
ively recorded just prior to LP at 0 hours and following
the LP at 1, 4 and 6 hours and daily for 7 days post-LP
using a paper diary. The paper headache diary was
returned by post 1 week after the LP, this was facili-
tated by a telephone reminder from the research nurse.
The headache severity NRS was further categorised
246 Cephalalgia 39(2)
into mild (1–3) moderate (4–6) severe (7–10) pain sever-
ity (17). We defined those with a change in the headache
severity score by 4 as a severe exacerbation.
Statistical analysis
Statistical analyses were undertaken on SPSS, Armonk,
NY: IBM Corp. Version 24.0 (2016). The characteris-
tics were generally described as median and interquar-
tile range (IQR) (non-parametric data) and headache
severity NRS as mean with standard deviation unless
otherwise stated. Mann–Whitney U test quantified
changes of clinical characteristics of patients that had
follow-up visits and the ones that deteriorated.
Wilcoxon signed-rank test and Friedman test were
used to compare changes in headache severity at differ-
ent time points. Spearman rank correlation quantified
the association between categorical variables and head-
ache severity. Data were further evaluated using a mul-
tiple linear regression model. A Bonferroni correction
was applied to account for multiple analyses. Only
patients with headache diary data that included base-
line, 1 hour and 7 days were included for analysis.
Where data was missing at other time points or for
other variables studied, this was noted in the results.
Statistical significance was considered at p< 0.05 level
(two-tailed) unless otherwise stated.
Results
Seventy headache diaries were returned. Four diaries
had insufficient data for analysis and were excluded.
The analysed cohort comprised 52 patients, and of
these 14 had second lumbar punctures performed
(Supplementary Table 1). Headache phenotype was
characterised at baseline; in this study, all patients
had active IIH, thus headaches were not primary head-
aches. However, based on phenotypic characteristics
using the International Headache Society ICHD-3
beta classification, we noted: Migraine-like or probable
migraine-like (n¼ 53, 80%), headache attributed to IIH
(n¼ 23, 35%), tension-type headache-like (n¼ 5, 8%),
other (n¼ 5, 8%) and not classifiable (n¼ 7, 11%)
(Table 1). Some participants had more than one head-
ache phenotype. We found no significant difference in
the baseline characteristics or headache outcomes fol-
lowing the first and repeat LP. The mean headache
score pre-LP was 3.6 2.8 on the NRS; 18% (12/66)
had severe headaches, 35% (23/66) had moderate head-
aches, 24% (16/66) had mild headaches and 23%
(15/66) had no headache on the day of the LP, at the
pre-LP time point.
Acetazolamide therapy was documented in 27% of
the patients with a median dose of 500mg and range
250–1500mg. No other diuretics were used. In all, 24%
used acute analgesics, of which 73% had paracetamol,
18% ibuprofen and 9% tramadol. One or more head-
ache preventatives were used by 24% of the patients:
63% topiramate, 44% amitriptyline, 13% gabapentin,
6% mirtazepine and 6% propranolol.
Therapeutic response to lumbar puncture
Seventy one percent improved at some point in the
week post-LP, with the greatest reduction in headache
severity occurring at 1 hour post-LP, but this was
Table 1. Baseline characteristics for the whole cohort including
data from all patient visits (n¼ 66). Data presented as median,
interquartile range (IQR) or percentage (visits) where specified.
Characteristic
Median
(interquartile range)
Age at baseline 31 (25–35)
BMI (kg/m2) 39 (35–47)
Weight (kg) 107 (93–120)
Pre-LP headache severity (NRS) 4 (1–6)
(mean 3.6 (SD: 2.8))
LP opening (cmCSF) 32 (28–37)
LP closing (cmCSF) 19 (17–21)
Amount CSF drained (ml) 10 (10–12)
RBC in CSF (cmm)# 7 (1–36)
Depth from skin to CSF (mm)
as measured by ultrasound##
67 (61–74)
Frise´n Grade Right eye 2 (1–2)
Left eye 2 (1–3)
Percentage (visits)
Ethnicity
White 91% (60)
Mixed/multiple ethnic group 5% (3)
Asian/Asian British 3% (2)
Black/African/Caribbean 2% (1)
Analgesic on day### 24% (11)
Headache preventative therapy 24% (16)
Acetazolamide 27% (18)
Headache phenotypes*
Migraine-like and probable
migraine-like
80% (53)
Attributed to IIH 35% (23)
Tension type-like 14% (9)
Other 8% (5)
Not classifiable 11% (7)
Note: Where data is missing, the number of visits included is indicated as
# ¼ 61, ## ¼ 22, ### ¼ 46.
*Patients may have experienced more than one headache phenotype at
baseline. Headaches exist in the setting of active IIH thus are not a pri-
mary headache; the phenotype of the headaches are classified according
to the ICHD-3 beta.
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a small improvement (1.1 2.6 NRS, p< 0.001), this
was maintained at 7 days (1.0 2.7 NRS, p¼ 0.004)
(Table 2, Figure 1(a),(b), Supplementary Figure 1(a)).
A more dramatic improvement was less common, with
an improvement by greater than 4 on the NRS noted in
32%. Twenty three percent of these patients experi-
enced an improvement that lasted at least two consecu-
tive days (Table 2).
A sensitivity analysis, excluding these, revealed that
the number of patients experiencing an improvement
was 92%, but the extent of the improvement
remained small (1.5 2.8 NRS, p< 0.001 at 1 hour
and by 7 days 1.5 2.5 NRS, p< 0.001) (Table 3,
Supplementary Figure 1(b), 1(c)).
Headache exacerbation post lumbar puncture
Sixty four percent experienced a headache exacerbation
at some point in the week following LP (Table 4).
Of note, a severe exacerbation by 4 points on the
NRS occurred in 30%. In 20%, this severe deterior-
ation lasted 2 days or more. Rates of improvement or
deterioration in the week after LP vary with baseline
headache severity (Tables 2, 4, Supplementary Figure
1). Deterioration was most evident at day 2 and 3 (com-
pared to the 1-hour time point, mean increase at day 2
of 1.5 3.4 NRS, p¼ 0.002 and at day 3, mean increase
of 1.5 3.1 NRS, p¼ 0.001) (Figure 1(a)).
Lumbar puncture outcomes analysed by baseline
headache severity
Severe headache pre-LP. Ninety two percent improved at
some point in the week following LP, with 42% experi-
encing an improvement of 4 on the NRS lasting at
least 2 days (Table 2). Deterioration was noted in 33%
over the week (Table 4). The extent of improvement
was 3.0 3.7 NRS, p¼ 0.024 at 1 hour and
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Figure 1. Headache severity following lumbar puncture, mean  standard error of the mean (SEM). (a) Whole cohort; (b) cohort
classified by baseline headache severity. NRS: numeric rating scale.
*p< 0.05, **p< 0.01, ***p< 0.001 (Wilcoxon signed-rank test).
Table 2. Pre-LP headache category and severity of the headache on the numeric rating scale (NRS) as categorised into mild (1–3)
moderate (4–6) severe (7–10) pain. It illustrates the % (number) of patients that had improvement in their headache at any point in the
week post-lumbar puncture (LP).
Pre-LP category % (number)
Improvement
by 4 on the
NRS, % (number)
Improvement
by 4 for 2 days
on the NRS, % (number)
All (n¼ 66) 71 (47) 32 (21) 23 (15)
All with headache (n¼ 51) 92 (47) 41 (21) 29 (15)
Those with no headache (n¼ 15)* N/A N/A N/A
Mild (n¼ 16) 81 (13) 0 0
Moderate (n¼ 23) 100 (23) 61 (14) 43 (10)
Severe (n¼ 12) 92 (11) 58 (7) 42 (5)
NRS: Numeric Rating Scale; N/A: Not applicable.
*On the day of the LP, at the pre-LP timepoint.
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3.0 2.8 NRS, p¼ 0.012 at 7 days (Table 3,
Figures 1(b) and 2(a) and (b)).
Moderate headache pre-LP. In those with moderate head-
ache pre-LP, improvement was noted in all (100%)
patients with 61% experiencing an improvement 4
on the NRS lasting at least 2 days (Table 2).
Deterioration was noted in 65% over the week
and 26% deteriorated by 4 points on the NRS
(Table 4).
The patients most likely to have improved at 1 hour
were those with moderate headache pre-LP (91% with
mean reduction of 2.2 1.6 NRS, p< 0.001) (Table 3,
Figures 1(b), 2(a), 2(b)). At 7 days, 61% of the patients
improved with mean improvement 1.7 2.3 NRS
(Table 3, Figures 1(b), 2(a), 2(b)).
Mild headache pre-LP. In those with mild headache pre-
LP, improvement was noted in 81% (Table 2).
Deterioration following LP was most pronounced in
those with mild headache pre-LP, with deterioration
noted in 81% (Table 4). The chance of severe deterior-
ation by 4 points on the NRS was 50% with
31% experiencing this for 2 days or more (Table 4).
In this group we observed that 44% (7/16) experienced
an exacerbation greater than seven on the NRS.
Table 3. Number of patients experiencing an improvement or deterioration in headache at 1 hour and 7 days post-lumbar puncture
(LP) compared to baseline. The p-values indicate the change between pre-LP and 1 hour or 7 days post-LP.
Baseline
Improvement
% of patients
(number)
Deterioration
% of patients
(number)
Change in
headache score
(NRS) mean  SD p-value**
Changes at 1 hour post-LP
All (n¼ 66) 58 (38) 20 (13) 1.1 2.6 0.001
All with headache (n¼ 51) 75 (38) 20 (10) 1.5 2.8 <0.001
No headache (n¼ 15)* 0 20 (3) 0.3 0.8 0.102
Mild (n¼ 16) 50 (8) 50 (8) 0.4 2.5 0.713
Moderate (n¼ 23) 91 (21) 4 (1) 2.2 1.6 <0.001
Severe (n¼ 12) 75 (9) 8 (1) 3.0 3.7 0.024
Changes at 7 days post-LP
All (n¼ 66) 47 (31) 18 (12) 1.0 2.7 0.004
All with headache (n¼ 51) 61 (31) 16 (8) 1.5 2.5 <0.001
No Headache (n¼ 15) 0 27 (4) 1.0 2.3 0.066
Mild (n¼ 16) 56 (9) 19 (3) 0.3 2 0.316
Moderate (n¼ 23) 61 (14) 22 (5) 1.7 2.3 0.007
Severe (n¼ 12) 67 (8) 0 (0) 3.0 2.8 0.012
NRS: Numeric rating scale.
*On the day of the LP, at the pre-LP timepoint, **Wilcoxon signed-rank test.
Table 4. Pre-LP headache category and severity of the headache on the numeric rating scale (NRS) as categorised into mild (1–3)
moderate (4–6) severe (7–10) pain. This illustrates the % (number) of patients that had deterioration in their headache at any point in
the week post-lumbar puncture (LP).
Pre-LP category % (number)
Deterioration
by 4 on the
NRS, % (number)
Deterioration
by 4 for 2 days
on the NRS, % (number)
All (n¼ 66) 64 (42) 30 (20) 20 (13)
All with headache (n¼ 51) 63 (32) 27 (14) 16 (8)
Those with no headache (n¼ 15)* 67 (10) 40 (6) 31 (5)
Mild (n¼ 16) 81 (13) 50 (8) 31 (5)
Moderate (n¼ 23) 65 (15) 26 (6) 13 (3)
Severe (n¼ 12) 33 (4) N/A N/A
N/A: not applicable.
*On the day of the LP, at the pre-LP timepoint.
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In the majority, the exacerbation was observed between
days 2–4 post-LP (Figures 1(b), Supplementary
Figure 1(d)).
No headache pre-LP. There was no headache present on
the day of the LP, at the pre-LP time point in 15
patients relating to the episodic nature of headaches
in some IIH patients (6). For the patients that did not
have a headache pre-LP, deterioration was noted in
67%. The chance of severe deterioration by 4 points
on the NRS was 40%, with 31% experiencing this in 2
days or more (Table 4).
Impact of lumbar puncture pressure and other
disease and procedural variables
The LP opening pressure did not affect the post-LP
headache severity. Furthermore, there was no relation-
ship between the headache response post-LP and the
BMI, height, depth from skin to CSF, Frise´n papilloe-
dema grade, LP closing pressure, number of LP
attempts, CSF red blood cell count, acute analgesics
use or the use of headache preventatives or acetazola-
mide. Further evaluation of those demonstrating a
deterioration of 4 points on the NRS found no rela-
tionship with the above factors. Only the headache
severity prior to LP showed an association with the
headache severity (p< 0.018, rho¼0.294 at 1 hour
and at 7 days (p< 0.001, rho¼0.402, (Figure 2(c),
Oldham’s methods) (18). There was no relationship
between headache phenotype and headache out-
comes; however, this study was not powered for this
subgroup analysis so meaningful conclusions cannot
be drawn.
Discussion
LPs maybe considered to relieve headache in patients
with IIH; however, the efficacy and potential risk of
post-LP headache exacerbation have not been previ-
ously defined. Whilst many patients and clinicians
expect beneficial effects of LP on headache severity in
IIH, this study has highlighted that this is not always
the case.
We have demonstrated that although the majority of
patients will experience an improvement in headache
severity, the extent of the improvement is small, and
the risk of a post-LP headache exacerbation is
significant.
Overall, we noted that 71% of patients noted head-
ache improvement after LP. This is comparable with
the only other prospectively collected data in this area
collected by the Danish Headache Center which noted
improvement in 72% of subjects at 10–15 minutes post-
LP (19). Of interest, our data evaluating headache
severity over the week following LP noted that
improvement was most marked by 1 hour post-LP
and predicted the improvement at 7 days.
Improvement in headache post-LP was small
(1.1 2.6 NRS at 1 hour and 1.0 2.7 at 7 days).
There is no consensus in the literature defining the min-
imally clinically important difference for a change in
headache severity. In pain literature, with a change of
greater than 2 in the score, NRS is judged to be clinic-
ally meaningful (20,21). Improvement post-LP was
greatest in those with severe headache pre-LP
(3.0 3.7 at 1 hour and 3.0 2.8 at 7 days) and is
likely to be more meaningful to patients. This is the
subgroup with the greatest benefit from LP (92%
improved). However, unfortunately this group were
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Figure 2. Changes in headache severity score (defined by the numerical rating scale (NRS)) post-LP. (a) Change in headache severity
score, data as mean  SEM; (b) percentage change in headache severity, data as mean  SEM; (c) correlation of change in headache
severity between baseline and 1 hour (y axis) with the mean pre-LP and 1 hour post-LP scores (x axis) using Oldham’s method,
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also susceptible to an exacerbation of their headache
(33%) at some point in the week after LP.
Those patients with moderate headache (NRS 4–6)
pre-LP also benefited (100% experienced an improve-
ment but again the extent was small (1.7 2.3 NRS
by 7 days)). However, the risk of a post-LP headache
exacerbation was considerable (65%).
Headache severity prior to LP was the only factor
that influenced the headache response post-LP.
Consequently, those with less headache at the time of
LP had the greatest chance of experiencing a post-LP
headache exacerbation (81% in those with mild head-
ache, NRS 1–3). Clearly, therapeutic LPs aiming to
relieve headaches are much less likely to be considered
in this group. However, knowledge of the risk of head-
ache exacerbation post-LP is important when consent-
ing patients undergo LP for diagnosis or assessment of
disease activity. Post-LP headache exacerbation can
lead to patients re-presenting to medical services fol-
lowing the LP. Of note, we have shown that 20% of
IIH patients will experience a deterioration by 4 NRS
that lasts at least two consecutive days.
The risk of headache exacerbation post-LP appears
higher than that noted in non-IIH patients (64% of IIH
versus 26% of non-IIH also with a traumatic needle)
(22). This may be due to the limited period of monitor-
ing post-LP in other studies. However, it is also pos-
sible that patients with intracranial pressure (ICP)
dysregulation could be more susceptible to fluctuations
in ICP.
The headache exacerbation post-LP described in this
study cannot be reliably stated as low-pressure head-
ache, as prolonged ICP monitoring was not utilised.
We did collect diary data on postural aspects of
the headache but did not feel this was reliable enough
to draw firm conclusions. In clinical terms, it is the
extent and rapidity of the headache alleviation on
lying that can identify low pressure headaches after
LP. The International Headache Classification
(ICHD-3 beta) definition of post-dural puncture head-
ache stipulates a headache that has developed within
5 days of dural puncture, which is not better accounted
for by another ICHD-3 beta diagnosis (16). This defin-
ition does not specify a postural component or take
into account the pre-LP headache. Consequently,
the headache exacerbations noted in our study are all,
by the ICHD-3 beta criteria, a post-dural puncture
headache. However, we cannot be certain when
differentiating a post-dural puncture headache from a
recurrence of baseline headache phenotypes. Future
studies could be more accurate in this differentiation
by using a physician or specialist nurse to assess the
headache phenotype at each time point or using an
ICP monitor.
We had hypothesised that IIH disease activity (papil-
loedema grade and CSF opening pressure), patient par-
ameters (weight, BMI, depth of CSF from skin as
measured by ultrasound, use of acute analgesics, head-
ache preventative or acetazolamide) and/or procedural
factors (red cell count, number of LP attempts, CSF
closing pressure) could influence headache outcomes
after LP. In the settings of this study design this was
not the case, with no relationship observed between any
of these factors. Of particular interest was the lack of
relationship between LP pressure and headache out-
comes. In keeping with this, headache disability in
IIH has been shown to be independent of LP pressure
(6) and the observation that LP opening pressure is not
related to headache response post-LP is of particular
interest and is corroborated by others (19). This could
suggest that the degree of ICP elevation is not the sali-
ent factor driving headache pain (19). Acetazolamide
dosage in this study was mean 500mg (range
250–1500mg) and only used by 27%, consequently we
cannot exclude whether higher acetazolamide doses
could have impacted on headaches outcomes.
The mechanism underlying the fluctuation in IIH
headache, post-LP, are not fully understood but may
include that the LP could create a CSF leakage with
ICP falling to a ‘‘normal’’ range for that patient, with
consequent improvement, or ICP could fall below the
‘‘normal’’ range for that patient, with consequent
deterioration in headache. Additionally, it is possible
that alternations in ICP could influence the generation
of migraine-like attacks.
Although the use of a standardised protocol for the
LP was essential for the aims of this study, it did not
allow us to investigate the effects of different needle
types or the impact of draining different CSF volumes
on headache severity. We acknowledge that the head-
ache responses could have been influenced by patients’
previous experience of LPs and by the information
relayed when consenting for LP (patients were aware
that headaches could exacerbate or improve after LP in
IIH patients). Additionally, conclusions cannot be
drawn regarding the effect of LP on ophthalmic symp-
toms or signs, as these were not assessed. It would be of
future interest to evaluate the role of LP in modifying
visual outcomes in cases with fulminant IIH and rapid
visual loss. Future studies evaluating patients over a
longer period post-LP would be of interest. It would
also be valuable to include a pre-LP headache diary to
further characterise the pre-LP headaches more accur-
ately. Additionally, evaluation of the effects of a sham
LP would be of interest to enable further interpretation
of the results. We acknowledge that the analysis of the
cohort by headache subgroup reduced the power of the
analysis but as the results were highly significant the
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impact of this analysis is unlikely to have changed the
meaning of the results.
In this study, we have highlighted that the only
factor which influences headache post-LP is pre-LP
headache severity. LP pressure does not influence the
post-LP headache. We have shown that after LP the
majority of IIH patients experience some improvement
over the following week (71%). But, of note, this bene-
fit is small (mean reduction of one point on the NRS)
and post-LP headache exacerbation is common (64%
deteriorate at some point in the week post-LP), and in
some cases this is prolonged and severe. However,
the greater the headache severity pre-LP, the greater
the likelihood of a therapeutic response to LP and the
least chance of post-LP headache exacerbation.
We would recommend that therapeutic LPs to treat
headache are only considered in those with severe
(NRS 7–10) headaches at baseline, and patients
should be aware that the improvements are modest
over the following week (92% will improve but the
mean improvement is a reduction of 3 on the NRS).
If patients are undergoing LP during the course of their
disease, the baseline headache severity should be noted
when consenting the patient on the likelihood of a post-
LP headache exacerbation: A third of those with no or
mild headaches (NRS< 3) pre-LP will have a signifi-
cant headache exacerbation (>4 on the NRS) lasting
>2 days. This is of relevance, as headaches in IIH are
frequently episodic (mean 12 days per month in the
IIHTT (6)), and it is consequently possible that patients
with disabling headaches may undergo LP on a day
when they do not have a headache attack. This study
does not allow us to comment on the utility of LP to
modify or protect vision.
Clinical implications
. Seventy one percent of IIH patients experience an improvement in headache at some point in the week
post-LP.
. The extent of headache improvement is small (reduction by one point on the NRS), but greater in those with
severe headaches, NRS 7, (reduction by three points on the NRS).
. Post-LP headache exacerbation is common in IIH (64%).
. LP pressure does not influence the post-LP headache.
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